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Everyday Memory Measures in Multiple Sclerosis: A Systematic
Review
Everyday memory is one of the most affected cognitive functions in Multiple
Sclerosis (MS). Assessing everyday memory problems is crucial for monitoring
the impact of memory deficits on individuals’ day-to-day lives and evaluating the
effectiveness of interventions that aim to improve cognitive functions. The aim of
this systematic review was to identify the research literature on everyday memory
measures used with people with MS, describe the types of measures used, and
summarise their psychometric properties. Empirical studies of cognitive function
in MS using standardised everyday memory measures were included. Online
databases (MEDLINE, PsycINFO, PsycARTICLES, Embase) and Google
Scholar were searched. Forty-four studies met the inclusion criteria. A total of
twelve measures were identified, with varied uses and administration methods.
The majority of papers did not report any psychometric properties for MS
populations. The few papers that did, reported that the measures have good
reliability and appear to have good face, concurrent and ecological validity, but
these need to be evaluated further. This review presents researchers and clinicians
with an overview of the various everyday memory measures used in studies with
people with MS, to help them choose the appropriate measure for their
evaluations.
Keywords: everyday memory; multiple sclerosis; systematic review;
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Introduction
Cognitive deficits affect up to 80% of individuals with Multiple Sclerosis (MS) (Fischer
et al., 2014), with attention, memory, information processing, and executive functions
being the most affected cognitive functions (Mackenzie, Morant, Bloomfield,
MacDonald, & O’Riordan, 2014; McIntosh-Michaelis et al., 1991; Rao, Leo, Bernardin,
& Unverzagt, 1991). Cognitive problems adversely affect individuals’ activities of daily
life, work, domestic, leisure and social activities, and cause distress and mood problems
for the individual with MS, their family and carers (Feinstein, 2006; Gilchrist & Creed,
1994; Peyser, Rao, LaRocca, & Kaplan, 1990).
Everyday memory refers to memory functions associated with daily life.
Examples include remembering names or faces, directions, shopping lists, locations of
objects, future events or appointments. Tests of everyday memory have questionnaire
items or activities that relate to, or closely resemble, routine everyday tasks. There is a
variety of everyday memory measures available, most of which are subjective patient-
reported measures (Chipchase & Lincoln, 2001; Sunderland, Harris & Baddeley, 1983).
Some ‘objective’ measures have also been developed to capture everyday memory
(Rendell & Craik, 2000; Smith, Della-Sala, Logie, & Maylor, 2000; Wilson, Cockburn
& Baddeley, 1985; Wilson et al., 2005).
The assessment of everyday memory problems is important for monitoring the
impact of memory deficits on an individual’s daily life throughout disease progression
and for evaluating the impact of interventions (e.g., memory rehabilitation) that aim to
improve cognitive functions or help people cope with cognitive problems. Several trials
of memory rehabilitation, however, have used impairment level measures of outcome,
and not functional outcomes that map onto the International Classification of
Functioning, Disability and Health’s domains of activity limitation and participation
restrictions, despite these domains being the focus of rehabilitation (World Health
Organization, 2007). In a recent Cochrane review only five out of 15 trials that
evaluated the effectiveness of memory rehabilitation in MS used subjective everyday
memory measures, and most used list-learning tasks as objective memory assessments
(das Nair, Martin, & Lincoln, 2016).
To our knowledge, no systematic review has been conducted on everyday
memory measures in MS (or any other clinical groups specifically), and this is the first
systematic review examining the use of these measures with people with MS.
Additionally, although the psychometric properties of the everyday memory measures
have been adequately demonstrated for the general population or other clinical groups,
we have a limited information with regards to their psychometric properties when used
with people with MS.
Our aim, therefore, was to systematically review the research literature on
everyday memory measures used with people with MS, describe the types of measures
used, summarise their psychometric properties in relation to their use with people with
MS, and describe how these measures have been used and what they have been used
for. We believe this review may help clinicians and researchers choose the appropriate
measures for their evaluations with people with MS.
Methods
A systematic search was conducted using the following electronic databases: Ovid
MEDLINE (R), PsycINFO, PsycARTICLES and Embase, from their inception until 2nd
May 2017. A search strategy was developed for Ovid MEDLINE (R) by two reviewers
(A2 and A3) in consultation with a third reviewer (A1) [Author names removed to
maintain the integrity of the review process]. Key words included: MS, disseminated
sclerosis, multiple sclerosis; combined with everyday memory, daily memory, and real
life memory. A two-step search process was used. First, an overview of everyday
memory measures was compiled from the book A Compendium of Tests, Scales and
Questionnaires (Tate, 2010). The name of each measure was combined with the above
mentioned search terms. The search strategy for the everyday memory measures is
available as supplementary material A. Second, where searches identified additional
everyday memory measures used with samples of people with MS, these were then
systematically searched in MEDLINE (2nd May 2017) and Google Scholar (24th
February 2017).
Papers obtained from the systematic search were independently screened by four
reviewers (A2, A3, A4 and A6) [Author names removed to maintain the integrity of the
review process]. Papers were initially screened by their titles and abstracts for
eligibility. The fifth reviewer (A1) confirmed eligibility [Author name removed to
maintain the integrity of the review process]. Eligibility of papers was determined
according to the following inclusion criteria: (a) study participants had a diagnosis of
any type of MS (relapsing-remitting, primary progressive, etc.); (b) participants were
over the age of 16 years; (c) everyday memory of the person with MS was assessed (as
outlined in the search strategy keywords) by the researcher/clinician, the individual with
MS or their carer; (d) papers reported peer-reviewed empirical studies (excluding
dissertations and protocols); (e) papers were available in English. Although measures
such as the Perceived Deficits Questionnaire (PDQ; Sullivan, Edgley, & DeHoux, 1990)
can be used as a screening tool of cognitive functioning for studies on any topic, for this
review we only considered studies using the PDQ where the focus of the study was
everyday memory.
A paper was discarded if the abstract clearly did not meet the inclusion criteria
or if it was a duplicate of another paper in the search results. Where the abstract
provided insufficient detail, full texts were accessed.
Three reviewers (A2, A3 and A6) independently extracted data from the full
texts. Any discrepancies were resolved through discussion, with another reviewer (A1)
arbitrating where necessary [Author names removed to maintain the integrity of the
review process]. All relevant data from the papers were entered onto a bespoke data
extraction form (Supplementary material B) to enable final decisions regarding
inclusion. We extracted the following data using a data extraction table (Supplementary
material C): Publication details, study aims and methods, participant demographics,
everyday memory measure used, how the measure was used, psychometric properties,
and conclusions.
Results
Characteristics of included studies
The database searches produced a combined total of 1201 hits from which 44 papers
were included in this review. These papers included studies from the UK (1, 4, 7-11,
26), Germany (2), Australia (3, 5, 12), USA (6, 13-21, 27, 33- 37, 39, 41, 43), Canada
(22, 23, 28, 42, 44), Italy (24), Finland (25, 31, 32), Iran (29), The Netherlands (30),
Greece (38) and Spain (40). Sixteen studies used correlational designs (1, 3, 6, 7, 13, 14,
18, 19, 23, 26, 27, 30, 37-39, 41), eleven had comparison group designs (2, 5, 12, 16,
21, 22, 25, 28, 29, 35, 44). Eight studies were randomised controlled trials (4, 9, 11, 17,
32, 40, 43), four were longitudinal (24, 34, 36, 42), two studies were quasi-experimental
(15, 33), one study was an extension of another study (31, 32), one study used a
retrospective design (8), one study used a survey design (10), and another was a
longitudinal case study (20). See figure 1 for PRISMA flow diagrams for Ovid and
Google Scholar searches (Moher, Liberati & Tetzlaff, 2009).
--------------------
Figure 1 here
-------------------
Characteristics of the samples
In total, 4402 people with MS participated in these studies, and 17 studies also included
healthy controls (n = 779) (2, 5, 8, 12, 18, 19, 21, 22, 25, 27-29, 34, 35, 37, 42, 44).
Some studies had mixed samples; three studies included informants (n = 368) (30, 35,
37), two studies included people with stroke (n = 107) (4, 8), one included participants
with traumatic brain injuries (n = 16) (4), and one included 51 carers of 51 people with
MS (1).
Demographics and illness characteristics of the samples
The mean age of the MS participants ranged from 35.9 to 71 years old (SD range 6.4 to
13.78), with the youngest being 17 and oldest 84 years old (8, 44). Gender weightings in
the sample were between 46% (21) to 100% women (20). Participants’ educational level
was variously coded in the studies. Thirty-six papers reported information on education
and of these, only 27 papers reported the mean years of education of the participants (3,
4-6, 12-14, 16, 18, 19, 21- 23, 25-27 31, 32, 34-37, 40-44). The mean years of education
ranged from 10.21 to 15.7 years for the overall sample (SD range 1.93 to 3.77). The
other nine papers reported education in the following ways: ‘levels’ of formal education
(2); the total number of participants within each education level (17, 23, 33, 30,); age at
which participants left education (16 years old; 9); percentages of the overall sample
(15, 38); and the participants’ highest qualification attained (20). Eight papers did not
report this demographic characteristic (1, 7, 8, 10, 11, 24, 29, 39).
Only 25 papers reported participants’ ethnicity, with 90% to 100% of the sample
reported as ‘Caucasian’ in 10 papers (13, 15-18, 27, 33-35, 39). African-American
people represented 3% to 14.3% in seven papers (15, 16-18, 27, 33, 39), American-
Indian represented 4% in one paper (27), and Hispanic people represented 1% to 5% of
the overall sample in four papers (15, 16, 18, 27). Other ethnic minorities were simply
described as ‘other’ in five papers (15, 16-18, 33) with one paper using the term ‘other’
with the exception of Asian or Pacific Islander, Native American or Hispanic (39).
Some participants had chosen not to provide details of their ethnicity and this was
reported as ‘declined’ in one paper (27). Two papers reported some ethnicity categories
but not others (34, 35).
Thirty-four papers specified the types of MS participants had, whereas ten did
not report this (1, 4, 5, 8, 10, 17, 29, 33, 38, 44). Three studies had samples of
participants with relapsing-remitting MS only (20, 31, 32). Most papers had mixed
samples with relapsing-remitting in 25 papers (2, 3, 6, 7, 9, 11, 12, 16, 18, 19, 21, 25-
28, 30, 34-37, 39- 43), primary progressive in 22 papers (2, 3, 6, 7, 9, 11, 14, 16, 19, 22,
27, 28, 30, 34-37, 39-43), secondary progressive in 26 papers (3, 6, 9, 11, 13-16, 18, 19,
21-23, 26-28, 30, 34-37, 39-43), progressive-relapsing in three papers (27, 35, 41),
clinically isolated syndrome in two papers (28, 30), and benign MS in one paper (11).
Type of MS was unknown in four papers (6, 7, 9, 11) and defined as ‘uncertain’ in one
paper (27).
Characteristics of everyday measures
There were 12 everyday measures identified in the 44 papers. In this section, we
describe the types of measures used, why they were used, how they were administered,
and the reported psychometric properties of these measures based on samples of people
with MS, as described by the studies using these measures.
Types of everyday measures
The MS Neuropsychological Questionnaire (MSNQ; Benedict et al., 2003) was the
most frequently used measure of everyday memory, used in 14 studies (15, 17, 23, 26,
28, 30-35, 37, 40, 42). Six studies also used the MSNQ informant version (15, 23, 30,
31, 37, 42). Eight studies used the Perceived Deficits Questionnaire (17, 31, 32, 36, 38,
39, 41, 44), and 6 studies used the Everyday Memory Questionnaire (EMQ; Sunderland
et al., 1983) (1, 4, 8-11). Five studies used the Prospective and Retrospective Memory
Questionnaire (PRMQ; Smith et al., 2000) (16, 18, 20, 22, 29). Four studies used the
Memory Functioning Questionnaire (MFQ; Gilewski et al., 1990) (6, 14, 15, 43) and
four used the Virtual Week task (Rendell et al., 2000) (5, 12, 20, 21). Three studies used
the Rivermead Behavioural Memory Test (RBMT; Wilson et al., 1985) (2, 4, 24), one
of which used its Extended version (Wilson et al., 1999) (4). Two studies used the
Cognitive Failures Questionnaire (CFQ; Broadbent et al., 1982) (7, 19) and two used
the Memory for Intentions Screening Test (MIST; Raskin, Buckeit & Sherrod, 2010)
(16, 27). The other tests used were the Cambridge Prospective Memory Test
(CAMPROMT; Wilson et al., 2005) (3), the Memory Rating Scale (MRS; Rao, 1984)
(13), and the Self-Evaluation of Everyday Memory and Learning Questionnaire (25).
The scoring, administration, reliability and validity of the measures are presented in
Table 1.
Uses of everyday memory measures
Eleven studies used everyday memory measures to correlate everyday memory with
another measure of memory (e.g., another everyday memory measure, or other memory
measures) (6, 13, 15, 18, 19, 30, 35, 36, 39, 41, 42), and 12 studies used measures to
correlate everyday memory with another variable (e.g., quality of life or mood) (13, 14,
18, 22-24, 27, 37-39, 41, 42). Everyday memory measures were also used as a predictor
variable (e.g., for quality of life or carer strain) in five papers (1, 3, 7, 37, 38) and a
predicted variable in three papers (19, 27, 34). In 23 studies, everyday memory
measures were used to compare the difference in performance between groups (e.g.,
between people with MS and healthy controls) (2, 4, 5, 9, 11, 12, 16, 17, 19, 21, 22, 25-
27, 29, 31, 32, 34-36, 40, 42, 43). Everyday memory measures were also used in seven
studies as outcome measures in randomised controlled trials of memory rehabilitation
(4, 9, 11, 17, 21, 31, 32). Other uses of everyday memory measures were to classify
people with MS as having impaired or unimpaired memory (10); to determine whether
people with MS had over-estimated or underestimated their cognitive ability (35); to
screen participants for eligibility into a trial (17, 28, 33); or as part of a battery to
describe memory deficits for a case study (20). Eight papers analysed the psychometric
properties of an everyday memory measure (8, 15, 23, 30, 34, 35, 37, 44).
Administration of Everyday Memory Measures
Everyday memory measures were mostly administered face-to-face (see Table 1) or this
was inferred from 27 papers (2-5, 9, 12, 14-16, 18-24, 26-28, 31, 32, 34, 35, 37, 40, 42,
43). They were also used as postal measures in seven studies (1, 4, 7, 10, 11, 30, 39), or
administered over the phone in two studies (17, 33). Only three papers explicitly
reported that the measure was self-administered (25, 30, 38) (we made an assumption in
the absence of information in the paper that when used as a postal measure, the measure
was self-administered). One paper posted the measure in a newsletter (44). Seven
papers did not report how the everyday memory measures were administered (6, 8, 13,
17, 29, 36, 41).
--------------------
Table 1 here
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Psychometric properties of Everyday Memory Measures
The following psychometric properties were reported for the reliability and validity of
the everyday memory measures as described within the included studies that used these
measures with samples of people with MS (see Table 2).
Of the six papers that used the EMQ, only one reported the internal consistency
reliability (8). Cronbach’s alpha was high (0.89) for the 13-item version of this scale.
Two papers reported on its validity, both reporting ‘good face validity’ (4, 8). One paper
assessed this by comparing the original scale with a 13-item revised scale, and also
assessed the construct validity by comparing patients with memory problems with
healthy participants (8).
Of the 14 papers that used the MSNQ, four reported on the internal consistency,
with two only referring to it as ‘reliable’ (23), and having ‘excellent internal
consistency’(35), and another two papers reported Cronbach’s alphas ranging from 0.93
to 0.95 (17, 30). Two papers reported on the interrater reliability, with one paper
referring to it as ‘moderate’ with an intraclass correlation coefficient of -0.59 (95% 0.49
– 0.69), along with low to moderate weighted kappa values for item scores (0.25 – 0.50)
(30). Another paper reported correlation scores between MSNQ-Self report and MSNQ-
Informant report scores (r = .55, p< .01) (37). Two papers reported on the test-retest
reliability; Cronbach’s alpha ranged from 0.86 to 0.90 for one of the papers (34),
whereas the other paper referred only to the measure having ‘excellent test-retest
reliability’ (35).
Validity was reported by five papers. Construct validity was reported in one
paper by testing six hypotheses by calculating Spearman correlations between the
MSNQ-P (self-report) and MSNQ-Informant report, an observational measure of
memory and measures of anxiety and depression (correlations ranged from 0.26 – 0.49)
(30). One study assessed construct validity via regression and reported R2 values ranged
from 0.28 – 0.40 and reported that two combined measures (the Symbol Digits
Modalities Test (SDMT; Smith et al., 1982) and the Beck Depression Inventory Fast
Screen (BDIFS; Benedict et al., 2003) accounted for a third of the variance in the
MSNQ (34). One study assessed the validity of the MSNQ discrepancy scores in all MS
patients who had either under-, over-, or accurately estimated neuropsychological
impairment, and then in a subgroup of cognitively impaired patients (35). This paper
reported discrepancy scores ranging from 16 – 30 (M = 21.1, SD = 3.6) in the under-
estimator group, -4 – 11 (M = 2.4, SD = 4.2) in the accurate estimator group, and -37 – -
11 (M = -20.6, SD = 7.4) in the over-estimator group. For MS patients categorised as
‘cognitively impaired’, discrepancy scores ranged from 16 – 30 (M = 20.6, SD = 4.3) in
the under-estimator group, -3 – 10 (M = 2.5, SD = 4.0) in the accurate estimator group,
and -37 - -11(M = -20.4, SD = 7.5) in the over-estimator group (35). The fourth paper
reported MSNQ sensitivity as .52 (95% confidence interval [CI] .32 - .72) and
specificity as 0.70 (95% CI .51 - .82) when categorising patients in the ‘global cognitive
impairment categories’ (37). With a cut-off score of 24 on the MSNQ, only 62% of the
MS patients were correctly categorised as either impaired or not impaired. A cut-off
score of 7.5 produced the maximum sensitivity (.90) and specificity (.96) for the MSNQ
(37).
Only one of the five studies that used the PRMQ reported the internal
consistency, with Cronbach’s alpha reported as 0.89, 0.84 and 0.80 (16). Again, validity
was not reported. None of the three papers using the RBMT reported the reliability or
validity of the measure, with only one paper suggesting that the test had been ‘validated
by five to ten years follow ups of patients with memory problems’ (p. 161) (2). Of the
four papers that used the Virtual Week, only one reported the split-half reliability
(Cronbach’s alpha ranged from 0.71 to 0.85) and none reported on the measure’s
validity (5). One of the two papers that used the CFQ reported the internal consistency
reliability (Cronbach’s alpha of 0.95) (7). Neither reported the validity. Only one of the
four papers using the MFQ referenced the internal consistency reliability of the measure
from other studies (Cronbach’s alpha ranged from 0.84 to 0.94) and also stated that the
measure ‘has demonstrated concurrent validity and convergent validity with another
commonly used metamemory measure’ (p. 265, 14) (Gilewski et al., 1990; Hertzog,
Hultsch, & Dixon, 1989; Randolph et al., 2004; Zelinski, Gilewski, & Anthony-
Bergstone, 1990). The study that used the CAMPROMPT reported inter-rater reliability
(r = .99) and ‘adequate test-retest reliability over 7-10 days (Kendall’s Tau-b = 0.64),
and suggested the measure was ‘ecologically valid’ (3). Of the two papers that used the
MIST, one paper referenced ‘strong evidence of reliability and construct validity’ (p.
890, 27) from other studies (Gupta et al., 2010; Woods et al., 2008), and one paper did
not report the reliability or validity (16). Of the eight papers that used the PDQ, only
two papers reported on reliability. One of the papers (36) reported internal consistency
by referencing Cronbach’s alpha ranges 0.77 – 0.97 from other studies (Fischer et al.,
1999; Marrie et al., 2003) and also reported test-retest reliability r = .564, p < .001. The
other paper reported internal consistency reliability from its own dataset with
Cronbach’s alpha ranging from 0.76 to 0.84 (44). Only three papers reported on the
validity of the PDQ. The first paper reported the PDQ has ‘good…validity in persons
with MS’ (p. 616, 36). The second paper did not find any correlations with objective
cognitive tests and was ‘uncertain’ as to what the PDQ assesses (39). The third paper
reported ‘the validity of self-report measures of cognitive problems may best be
addressed by examining whether these measures predict disruptions in daily living, not
whether they predict neuropsychological test scores’. (p.103, 44). Papers using the
MRS-C (13), and the Self-Evaluation of Everyday Memory and Learning Questionnaire
(25) did not report on the reliability or validity of the measures.
--------------------
Table 2 here
-------------------
Discussion
Everyday memory measures were used with a wide age range of people diagnosed with
MS, with the mean number of years of education ranging from 11 to 15.7 years. Most of
the participants were women and of White ethnicities, which is representative of the MS
population. All MS sub-types were represented in the literature. Of the 12 everyday
measures identified in the 44 papers, the majority were questionnaires, with only four
being observer-assessed ‘objective’ tests that required the respondent to follow certain
actions. These objective measures were the RBMT, CAMPROMPT, Virtual Week, and
MIST.
Everyday memory measures were used for a variety of reasons: to assess how
different everyday memory measures compare with each other, how everyday memory
relates to other symptoms of MS (such as mood problems), and whether everyday
memory can predict an outcome. Everyday memory measures were also used to screen
participants for memory problems, and to classify and describe people’s memory
problems. Some trials of cognitive rehabilitation used everyday memory measures as a
primary or secondary outcome to evaluate the impact of the intervention on everyday
memory performance.
The variability of the use of these measures also suggests their versatility. Their
versatility is also reflected in their administration formats, with the everyday memory
questionnaires being administered face-to-face, over the phone, or by post. The
questionnaires could also be self-administered. This is important for their use as
outcome measures in intervention trials, because most of these trials are observer-
blinded and the chances of the outcome assessor becoming unblinded increases if they
are in direct contact with participants. Indeed, many trials have imperfect blinding
(Fergusson et al., 2004). This gets more difficult with participants with memory
problems who even when told not to reveal their group allocation sometimes forget this
instruction and inadvertently unblind the assessor (Lincoln, personal communication,
2017).
The majority of papers did not report or reference information related to
reliability. Of the measures that did discuss reliability, one reported test-retest reliability
(Kendall’s Tau = b-0.64) (Honan et al., 2015) and inter-rater reliability (r =.99), and six
discussed internal consistency (Cronbach’s alphas ranging from 0.80 to 0.95). The
validity of the measures was even less frequently presented. Where validity was
discussed most authors presented a verbal description of the face validity, concurrent
validity with independence and employment, and ‘ecological validity’. Ecological
validity refers to the extent to which cognitive tests relate to cognitive problems in daily
living or functional limitations, emphasising how these tests predict function in real-life
settings (Ginsberg, Kibby & Long, 1996). Higginson et al. (2000) highlight the EMQ
and RBMT as examples of ecologically valid tests of memory for use with people with
MS; the EMQ, a rating scale assessing the frequency and of real-life memory problems,
and the RBMT, a test which assesses analogues of everyday memory situations. Their
study, which compared ecologically valid measures (memory questionnaires and tests)
with standard neuropsychological tests (e.g., list learning and symbol-digit modalities
test), found that the ecologically valid tests were better predictors of functional
disability than both memory questionnaires and standard neuropsychological tests
commonly used in assessing people with MS. The lack of correlations between some of
these tests suggested that the ecologically valid tests measured something different than
what was measured by the standard neuropsychological tests.
Everyday memory measures, therefore, have an important role to play in
assessing memory functions in people with MS, predicting functional disability,
establishing how everyday memory relates to other symptoms of MS, evaluating change
over time, and examining the effectiveness of interventions.
One limitation of our review is that we did not assess the risk of bias or
methodological quality of the included papers through a standardised checklist. Our aim
was to clearly report all available evidence and synthesise findings, rather than
presenting the ‘weight’ of the evidence. Thus, we cannot determine whether the
included studies provide robust or generalisable findings.
Conclusions
This review presents researchers and clinicians with an overview of the various
everyday memory measures that have been used in studies with people with MS.
Everyday memory measures have been used for a variety of reasons with people with
MS of different demographics and different MS subtypes. These measures are often
questionnaires or objective tests with prescribed activities. The questionnaires are
versatile, can be self-administered and can be used over the telephone or by post. Both
the questionnaires and tests have been used as outcome measures in trials of cognitive
rehabilitation. The measures have good reliability and appear to have good face,
concurrent and ecological validity, but these need to be evaluated further in samples of
people with MS.
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Table 1. Scoring, administration, reliability and validity of EM measures
Questionnaires/
Tests
Number of
items/subtests
Scaling and scoring Administration
time
Administration modality Reliability and validity
CFQ 25 items Likert scale scored 0
(never) to 4 (very
often)
Not reported Two papers reported
using postal
administration (7) and
face-to-face
administration (19)
The factor structure of the CFQ varied
between occupational groups (Broadbent
et al., 1982).
EMQ 35 items (28 in
revised version)
Likert scale scored 0
(never) to 4 (more
than once a day).
Total score is sum of
all items.
Not reported Five papers reported
using postal and inferred
postal administration (1,
4, 10, 11) and inferred
face-to face (9)
MFQ 64 items, 7
sections
7 point Likert scale
(never to always)
Not reported Three papers reported
face-to-face and inferred
face-to-face
administration (14, 15,
43)
MRS-C 31 items Likert scale scored 1
(much worse than the
average person) to 5
(much better than the
average person)
Not reported Not reported
Questionnaires/
Tests
Number of
items/subtests
Scaling and scoring Administration
time
Administration modality Reliability and validity
MSNQ 15 items Likert scale scored 0
(never) to 4 (very
often)
Not reported Thirteen papers reported
using face-to-face or
inferred face-to-face
administration (15, 23,
26, 28, 31, 32, 34, 35, 37,
40, 42), self-
administration and postal
administration (30) and
telephone administration
(33)
“Cronbach's alpha coefficients were 0.93
and 0.94 for the patient- and informant-
report forms, respectively, and both forms
of the test were strongly correlated with a
more general cognitive complaints
questionnaire. The patient MSNQ form
correlated significantly with measures of
depression but not with objective tests of
cognitive function. In contrast, the
informant form was correlated with
patient cognitive performance but not
depression. A cut-off score of 27 on the
informant form of the MSNQ optimally
separated patients based on a
neuropsychological summary score
encompassing measures of processing
speed and memory. There were two false-
negatives and one false-positive, giving
the test a sensitivity of 0.83 and a
specificity of 0.97” (Benedict et al., 2003)
PDQ 20 items Likert scale scored 1
(never) to 5 (almost
always)
Not reported Six papers reported using
telephone administration
(17), inferred face-to-face
( 31, 32), self-
administration (38), postal
administration (39) and
Analyses revealed that the 4 subscales
were internally consistent:
attention/concentration (alpha=0.78),
planning/organization (alpha=0.84),
retrospective memory (alpha=0.83),
prospective memory (alpha=0.76).
Principal components analysis with
Questionnaires/
Tests
Number of
items/subtests
Scaling and scoring Administration
time
Administration modality Reliability and validity
posted in a newsletter
(44)
oblique rotation yielded a 4-factor
solution that paralleled the subscale
structure. Inter-factor correlations
averaged 0.45 (p.102) (44).
PRMQ 16 items Likert scale scored 1
(never) to 5 (very
often)
Not reported Four papers reported
using face-to-face and
inferred face-to-face
administration (18, 22,
16, 20)
Has self and proxy rating versions,
normative data from 555 healthy controls
aged 17-94 years (Crawford et al., 2003).
“We examined the split half reliability of
the questionnaire, comparing the two
questions within each category from the
elderly and young control participants
only (n= 406). Using the Spearman-
Brown formula, the split half reliability
was rSB=0.84.” (p. 315) (Smith et al.
2000)
Self-evaluation of
memory and
learning
Data
Unavailable
Likert scale scored 1
(never) to 5 (often)
Not reported Self-administered From personal communications with
author (24th August 2016), no
psychometric properties were available.
CAMPROMPT 6 tasks Data unavailable 25 mins Needs trained
administrator; Face-to-
face
MIST 8 tasks 6 subscales ranging
0-8, summed into
summary score
ranging 0-48
30 mins Needs trained
administrator; face-to-
face
Questionnaires/
Tests
Number of
items/subtests
Scaling and scoring Administration
time
Administration modality Reliability and validity
RBMT 14 tasks Gives standardised
scores and percentile
rank with cut-off data
for impairment level
30 mins Needs trained
administrator; Face-to-
face
Virtual Week 3 different types
of tasks
Scored on tasks
correct, incorrect,
late or missed.
75-120 mins Needs trained
administrator; Board
game or computerised,
individual or group
Note. Abbreviations: CAMPROMPT: Cambridge Prospective Memory Test; CFQ: Cognitive Failures Questionnaire; EM: Everyday memory; EMQ:
Everyday Memory Questionnaire; MFQ: Memory Functioning Questionnaire; MIST: Memory for Intentions Screening Test; MRS: Memory Rating Scale;
MS: Multiple Sclerosis; MSNQ: MS Neuropsychological Questionnaire (MSNQ-P: patient self-report version; MSNQ-I: Informant version); PDQ: Perceived
Deficits Questionnaire; PRMQ: Prospective and Retrospective Memory Questionnaire; RBMT: Rivermead Behavioural Memory Test.
Table 2. Reliability and validity of EM measures in MS samples
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
EMQ (6)
Not Reported
The EMQ ‘has good face validity,
assesses real-life situations…’ (p.897)
(das Nair et al. 2012)
‘…and is used in clinical practice’
(p.897) (das Nair et al. 2012)
‘Cronbach’s alpha for the scale was
high (0.91)’ (p.117) (Royle et al.
2008) (controls only)
‘Cronbach’s alpha for the shortened
scale was high (0.89) and all items
showed corrected item-total
correlations of at least 0.3,
indicating strong internal reliability’
(p.117-8) (Royle et al. 2008) (both
groups)
‘…good face validity’ (p. 114) (Royle et
al. 2008)
‘Further evidence of the validity of the
revised scaled was confirmed by the
strong relationships between the original
and revised versions, suggesting that the
revised 13-item questionnaire could
provide a valid and reliable tool for
clinical use…’ (p.119) (Royle et al.
2008)
The EMQ ‘was initially developed for
use with survivors of head injury
…further refined…with both non-
clinical and clinical samples’. (p. 115)
(Royle et al.2008)
‘The original questionnaire consisted of
35 items, which has since been altered
to 28-item questionnaire to increase the
measure’s validity and facilitate self-
administration’. (p. 115) (Royle et al.
2008)
Not Reported Not Reported
‘The outcome measures used (including
EMQ) may not be appropriate to detect
the benefits of providing an
intervention’ (p.97)(Lincoln et al. 2002)
Not Reported Not Reported
‘Only a few items from the Everyday
Memory Questionnaire completed by
the person with MS were associated
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
with carer strain, and there was no
apparent difference between those items
that were related…and those that were
not…’ (p. 772) (Chipchase et al. 2001)
Not Reported Not Reported
Not Reported Not Reported
The EMQ ‘was used as there was no
appropriate alternative available with
good psychometric properties’ (p.559)
(Carr et al. 2014)
MSNQ (14)
Not Reported Not Reported
The MSNQ ‘appears reliable to
detect cognitive impairment (p.410)
(Stuifbergen et al. 2012)
Not Reported
‘There was a strong correlation between
the results obtained on the
neuropsychological tests at least for
memory functioning, and the score on
the MSNQ-informant.’ (p.413)
(Stuifbergen et al. 2012)
‘The Cronbach’s alpha for internal
consistency reliability ranged from
0.94 to 0.95’ (p.886) (Cutajar et al.
2000)
Not Reported
MSNQ ‘scores were significantly
correlated with scores on a battery of
neuropsychological tests and measures
of whole-brain lesion burden and
atrophy in prior research’ (p.886)
(Cutajar et al. 2000) (Benedict et al.
2004; Benedict & Zinadinov, 2006)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
Not Reported Not Reported
Not Reported Not Reported
Cronbach’s alpha for MSNQ-P 0.93
and MSNQ-I 0.94 showed good
internal consistency.
Interrater reliability between
MSNQ-P and MSNQ-I was
moderate, with Intraclass
Correlation coefficient of 0.59 (95%
CI: 0.46-0.69).
Weighted kappa values for item
scores were low to moderate (0.25-
0.50)
Construct validity was confirmed
through six hypotheses:
1) Correlation between MSNQ-P
and BRBN small positive, 0.26
2) Correlation between MSNQ-I
and BRBN moderate and
positive, 0.39
3) Correlation between MSNQ-P
and anxiety and depression
scales (HADS) moderate and
positive, 0.49 and 0.47
respectively
4) Correlation between MSNQ-I
and anxiety and depression small
positive, 0.36 and 0.33
5) Correlations between MSNQ-P
and BRBN small positive, 0.26
and correlation between MSNQ-
I and BRBN is higher , 0.39
6) Correlation between MSNQ-P
and anxiety and depression, 0.47
‘Internal consistency was good for both
scales. Assessment of construct validity
showed that all hypotheses based on
previous studies were confirmed
(Benedict et al. 2003; Vanotti et al.
2009)’.
‘The interrater reliability of the total
score and the item scores between the
patient and informant versions was
moderate’.
‘Interrater agreement was poor’.
‘The main outcome is that the MSNQ-I
is more promising to screen for
cognitive impairment in MS patients.
The patient version has no added value,
so when screening for cognitive
impairment in MS the MSNQ version is
preferred’. (p. 95) (Sonder et al. 2012)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
and 0.49 respectively.
Correlation between MSNQ-I
and anxiety and depression is
lower, 0.33 and 0.36
respectively. (p. 94) (Sonder et
al. 2012)
Not Reported Not reported
Not Reported Not Reported
Not Reported Not Reported
‘Test-retest correlations ranged
from.0.86 [test 2 to test 3] to 0.90
[test 3 to test 4 for MSNQ.’ (p. 943)
(Benedict et al. 2008)
‘Our results clearly show that
SDMT and MSNQ are reliable when
administered by nursing staff at
monthly intervals.’ (p. 944)
(Benedict et al. 2008).
‘Test-retest coefficients were
acceptable to strong for both tests
and showed very little variation over
the course of the study.’ (p. 944)
(Benedict et al. 2008)
R2 final model:
Month 2=0.40 (BDIFS and SDMT),
Month 3=0.37(BDIFS), Month 4=0.38
(BDIFS), Month 5=0.28 (BDIFS and
SDMT), Month 6=0.38 (BDIFS and
SDMT)
‘The final R2 values ranged from 0.28 to
0.40, suggesting that SDMT and BDIFS
combined account for roughly 1/3 of the
variance in MSNQ.’
‘The question of validity was also
examined in the regression models
where we attempted to determine the
‘The current findings parallel previous
showing good test-retest reliability with
these measures using a weekly
assessment schedule (Benedict et al.
2004; Benedict, Cox, Thompson et al.
2004)(p.944) (Benedict et al. 2008)
(post hoc rationale) ‘The high reliability
for the SDMT and MSNQ when used on
a monthly basis means that these tests
can be used to identify patients at high
risk for neuropsychological compromise
with minimal error, in the clinic setting.’
(p. 944) (Benedict et al. 2008)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
most significant correlate of the
MSNQ…..it was understood that
correlations between MSNQ and tests of
depression were higher than with
neuropsychological testing.’ (p. 944)
(Benedict et al. 2008)
‘The test has excellent internal
consistency and test-retest reliability
(Benedict et al. 2003; Benedict et al.
2004)(p. 575) (Carone et al. 2005)
MSNQ Discrepancy scores for all MS
patients:
Underestimator group: 16-30 (M=21.1,
SD=3.6)
Accurate estimator group: -4 – 11
(M=2.4, SD= 4.2)
Overestimator group: -37 - -11 (M=-
20.6, SD=7.4)
MSNQ Discrepancy scores for
cognitively impaired MS patients:
Underestimator group: 16 – 30
(M=20.6, SD=4.3)
Accurate estimator group: -3 – 10
(M=2.5, SD=4.0)
Overestimator group: -37 - -11 (M=-
20.4, SD=7.5)
‘While the validity of such informant
report questionnaire responses is
demonstrated in MS (Benedict et al.
2003), and other conditions (Koss et al.
1993; McGlone et al. 1990) ;
Sunderland et al., 1983), it falls short of
actual observation and could be subject
to report bias on part of the informants’.
(p. 581) (Carone et al. 2005)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
‘…our study assessed the validity of the
MSNQ discrepancy scores in all MS
patients first, and then in a subsample of
cognitively impaired patients…we
found that discrepancy scores reflecting
over-estimation of ability were
associated with poor
neuropsychological test performance in
both analyses’. (p. 580) (Carone et al.
2005)
Interrater reliability: Correlation
between MSNQ-S and MSNQ-I
scores r=.55, p<.01
Sensitivity and Specificity:
MSNQ-S demonstrated sensitivity=.52
(95% confidence Interval (CI) .32- -
.72) and specificity= .70 (95% CI .51 -
.82) when categorising persons in the
global cognitive impairment categories,
utilising the recommended cut-off score
of 24.
MSNQ-I demonstrated sensitivity=.66
(95% CI .44 - .84) and specificity=.77
(95% CI .56 - .89) when categorising
persons in the global cut-off score
‘With a cut-off score of 24 on the
MSNQ-S, only 62% of the MS sample
was correctly classified as either
impaired or not impaired.
A cut-off score of 22 on the MSNQ-I
resulted in 70% of the MS sample
correctly classified as either impaired or
not impaired.’ (p. 943) (O’Brien et al.
2007)
‘Results showed that the MSNQ-I
appears to be a useful screening measure
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
utilising the recommended cut-off score
of 22.
ROC curve analysis: MSNQ-S, area
under ROC Curve is .62% (S.E.=.09, p>
.05). This value was not significant.
In the current study, a score of 7.5 on
the MSNQ-S produced maximum
sensitivity (.90) and specificity (.96) for
this measure.
MSNQ-I, area under ROC curve is .74
(S.E=.08, p> .05. This did not provide a
strong support for the ability to
differentiate between cognitively
impaired and non-impaired groups. In
this current study, a score of 10 on the
MSNQ-I produced the maximum
sensitivity (.94) and specificity (.55) for
this measure. (p.943-45) (O’Brien et al.
2007)
for cognitive impairment in persons with
MS’. (p. 945) (O’Brien et al. 2007)
Not Reported Not Reported
Not Reported Not Reported
‘Of note is that both self and informant
MSNQ findings did discriminate
between the MS and healthy control
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
groups at both baseline and follow-up’.
(p.150) (Walker et al. 2016)
PRMQ (5)
Not Reported Not Reported
(post hoc rationale) ‘One can also
question the reliability of the answers
given on the PRMQ. However there are
two arguments in favour of the
reliability of the data. On the one hand,
there is the effect size…on the other
hand, there is convergence between
some of our results and those obtained
by others…’ (p. 732-733) (Demers et al.
2011)
Cronbach’s alpha 0.89, 0.84, 0.80
(p. 401)
Not Reported
Not Reported Not Reported
‘The PRMQ can be broken down into
prospective and retrospective memory
factors… given a very high correlation
between these factors (r>.80)’ (p. 41)
(Bruce et al. 2010)
Not Reported Not Reported
Not Reported Not Reported
RBMT (3) Not Reported
‘Furthermore, this test has been
validated by five to ten years follow ups
‘The RBMT has shown to correlate well
to results of traditional memory tests
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
of patients with memory problems, thus
showing a close association between
test performance and independence
and/or employment’ (Wilson et al.
1991) (p.161) ( Haupts et al. 1994)
such as the Wechsler Memory scale and
subjects’ self-assessment
reports’(Lincoln & Tinson, 1989)
(p.161) (Haupts et al. 1994)
Not Reported Not Reported
Not Reported Not Reported
‘It evaluates the mnemic function
understood in its ‘ecological’ sense’. (p.
189) (Cutajar et al. 2000)
Virtual Week (4)
Split half reliability of tasks for MS
group: regular (.85), irregular (.71),
time check (7.1) (.79, .75, .73 for
controls) (p. 742) (Rendell et al.
2012)
Not Reported
‘Virtual Week is a laboratory measure
of PM that closely represents the types
of PM tasks that actually occur in
everyday life’ (p. 739) (Rendell et al.
2012)
Not Reported Not Reported
‘It has been found to be very sensitive to
the effects of ageing on prospective
memory (Rendell & Craik, 2000) and
also discriminates between patients with
bipolar disorder and healthy controls’ (
Rendell et al. 2012) (p. 411) (Rendell et
al. 2007)
Not Reported Not Reported
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
Not Reported Not Reported
‘…this board game has been found to be
sensitive to PM deficits in other
populations, as well…’ (p747)
(Kardiasmenos et al. 2008)
CFQ (2)
Cronbach’s alpha was 0.95. (p. 103)
(Phillips et al. 2009)
Not Reported
‘There are also indicators from previous
studies that the CFQ and ERQ are
associated with objective indicators of
performance’ (see Robertson et al.
1997) (TBI study)). (p. 104) (Phillips et
al. 2009)
Not Reported Not Reported
MFQ (4)
Not Reported Not Reported
‘The dependant variable used in these
analyses was the Total MFQ score,
which has a possible range of 64 (lowest
rating of one’s memory faculties) to 448
(highest rating).’ (p. 558) (Krch et al.
2011)
‘internal consistency of factors
ranging from 0.84 to 0.94
across’(Gilewski et al. 1990;
Zelinski et al. 1990) (p. 265)
(Randolph et al. 2004)
‘…has demonstrated concurrent validity
with memory performance measures
and convergent validity with another
commonly used metamemory measure’.
(Zelinski et al. 1990; Hertzog et al.
1989) (p. 265) (Randolph et al. 2004)
‘Associations were found between MFQ
scales and various measures of
depression and cognitive functioning…’
(p. 275) (Randolph et al. 2004)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
Not Reported Not Reported
Not Reported Not Reported
CAMPROMPT
(1)
‘Excellent interrater reliability (r=
.99), adequate test-retest reliability
over 7-10 days (Kendall’s Tau-b=
.64).’ (p. 158) (Honan et al. 2015)
The CAMPROMPT ‘is an ecologically
valid 25-min measure of prospective
memory’ (p, 158) (Honan et al. 2015)
The CAMPROMPT ‘is moderately
correlated with other measures of
memory, attention and executive
functioning (Wilson et al., 2005), and
can also distinguish the performance of
those with MS from healthy
controls’(Foley et al. 2004) (p. 158)
(Honan et al. 2015)
MIST (2) Not Reported Not Reported
The MIST ‘demonstrates strong
psychometric properties and has been
shown to accurately reflect prospective
memory in a variety of neurologic
patient populations’(Woods et al. 2008;
Raskin et al. 2009) (p. 401) (Thelen et
al. 2014)
Not reported for the current sample
‘The research version of the MIST
shows strong evidence of
reliability’(Woods et al. 2008) (p.
890) (Miller et al. 2014)
Not reported for the current sample
‘…and construct validity ‘(Gupat et al
.2010) (p.890) (Miller et al. 2010)
‘As such the current study extends the
external validity of the initial findings.’
(p. 892)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
MRS-C (1) Not Reported Not Reported
‘Adapted from the Everyday Memory
Questionnaire, the MRS-C is composed
of 31 items that ask participants to
compare their current ability to
remember day-to-day information with
that of the average person’. (Sunderland
et al. 1983) (p. 204) Bruce & Arnett
2004)
PDQ (8) Not Reported Not Reported
Not Reported Not Reported
‘The reliability and validity of the
MSQLI (Fischer et al. 1999) and PDQ
have been shown in patients with MS’
(Marrie et al. 2003) (p. 103) (Mäntynen
et al. 2014)
Not Reported Not Reported
‘The PDQ has good reliability…in
persons with MS (Cronbach’s alpha
for five item PDQ reported between
0.77-0.97’ (Fischer et al. 1999;
Marrie et al. 2003) (p.
616)(Christodoulou et al. 2005)
‘The PDQ has good….validity in
persons with MS…’(p.616)
(Christodoulou et al. 2005)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
Test-retest reliability r=.564, p<.001
(p.616) (Christodoulou et al. 2005)
Not Reported Not Reported
Not Reported
‘Since the PDQ did not correlate with
any of the objective cognitive tests used
in this study, what the PDQ actually
assesses is uncertain.’ (p. 81) (Lovera et
al. 2006)
Not Reported Not Reported
‘Reports of cognitive concerns on the
PDQ were highly correlated with
concomitant reports of depression,
anxiety, fatigue and self-efficacy, in line
with existing literature’ (Lovera et al
2006; Kinsinger et al. 2010; Lester et al.
2007). (p. 187) (Strober et al. 2016)
The 4 subscales were internally
consistent: attention/concentration
(Cronbach’s alpha)=.78,
planning/organization (Cronbach’s
alpha)=.84, retrospective memory
(Cronbach’s alpha)=.83, prospective
memory (Cronbach’s alpha)=.76.
‘Concerns have been raised about the
validity of self-report measures of
cognitive functioning’ (Herrman et al.
1984)
‘For example, the current findings
indicate that individuals with MS
reported experiencing difficulties in
‘The results of the survey also indicated
a high prevalence of spontaneous
utilisation of strategies to deal with
cognitive difficulties. The most
commonly reported strategy was a use
of an external memory aid.’ (p. 103)
(Sullivan et al. 1990)
EM Measure
(no. of papers
used in)
Reliability in MS samples Validity in MS samples Other Comments
Inter-factor correlations
averaged=.45
prospective memory, and planning and
organization’.
‘The validity of self-report measures of
cognitive problems may best be
addressed by examining whether these
measures predict disruptions in daily
living, not whether they predict
neuropsychological test scores’. (p.103)
(Sullivan et al. 1990)
Self-evaluation of
everyday memory
and learning (1)
Not Reported Not Reported
From personal communications with
author (24th August 2016) this was a
unitary scale that was self-administered.
No psychometric properties were
available.
Note. Abbreviations: BDI-FS: Beck Depression Inventory-Fast Screen; BRBN: Brief Repeatable Battery of Neuropsychological Tests; CAMPROMPT:
Cambridge Prospective Memory Test; CFQ: Cognitive Failures Questionnaire; EM: Everyday memory; EMQ: Everyday Memory Questionnaire; ERQ:
Emotion Regulation Questionnaire; HADS: Hospital Anxiety and Depression Scale; MFQ: Memory Functioning Questionnaire; MIST: Memory for Intentions
Screening Test; MRS: Memory Rating Scale; MS: Multiple Sclerosis; MSNQ: MS Neuropsychological Questionnaire (MSNQ-P: patient self-report version;
MSNQ-I: Informant version); MSQLI: Multiple Sclerosis Quality of Life Inventory; PDQ: Perceived Deficits Questionnaire; PM: Prospective memory;
PRMQ: Prospective and Retrospective Memory Questionnaire; RBMT: Rivermead Behavioural Memory Test; ROC: Receiver Operating Characteristic;
SDMT: Symbol Digit Modalities Test; TBI: Traumatic Brain Injury.
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Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
1 Chipchase &
Lincoln
(2001)
UK
51
(informal
carers=
51)
58 M=44
SD=9.41
Range= 26-
64
Not Reported Not
Reported
Not Reported EMQ Postal
administration
at 2 time points
(baseline & 4
months after
recruitment)
As a predictor
variable for carer
strain
2 Haupts et al.
(1994)
Germany
35
(healthy
controls=
30)
63 M=35.9
SD=+/- 7
Range=21-61
‘Education
was scored in
levels of
formal
education…’
(p. 159) Not
reported in
years
Not
Reported
FM=6
RR=20
PP=9
German RBMT Face to face
inferred.
Administration
at one time
point
To compare EM
tasks between MS
and control groups
3 Honan et al.
(2015)
Australia
111 70 In paid
employment
M=44.34
SD=10.35
unemployed
M=50.94
SD=10.53
Expressed
according to
employment
status
In paid
employment
Not
Reported
In paid
employment
RR=46
SP=10
PP=3
Other=3
unemployed
CAMPROMPT Face to face
inferred.
Administration
at one time
point
As a predictor
variable for work
outcomes
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
M=13.82,
SD=2.17
Unemployed
M=14.37,
SD=2.32
RR=28
SP=13
PP=5
Other=3
4 dasNair &
Lincoln
(2012)
UK*
MS=39
TBI=16
Stroke=17
56a M=47.7a
SD=10.2a
Expressed
according to
intervention
group
allocation
Compensatio
n group
treatment:
M=13.5,
SD=2.6
Restitution
group
treatment:
M=13.6,
SD=2.6
Self-Help
group
control:
Not
Reported
Not Reported EMQ
RBMT
EMQ: Postal
inferred. RBMT:
Face to face
inferred.
Administered at
3 time points
(baseline, 5
months and 7
months after
randomisation)
EMQ: Primary
outcome
RBMT: secondary
outcome measure.
To compare EM
between
intervention and
control group
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
M=12.4,
SD=2.1a
5 Rendell et al.
(2012)
Australia
30
(healthy
controls=
30)
80 M=47
SD=9.46
Range=28-60
M=14.2
SD=3.14
Not
Reported
Not Reported Virtual Week Computer
administration
in the lab at one
time point
To compare PM
between MS and
controls across
positive, negative
and neutral
emotional task
conditions
6 Krch et al.
(2011)
USA
64 75 M=47.7
SD=+/-9.3
Range=18-55
M=15.7
SD=+/- 2.4
Not
Reported
RR=47
PP=2
SP=1
Unknown=1
MFQ Administration
method not
reported.
Administered at
one time point
To correlate
subjective memory
with other
cognitive tests
(objective memory)
7 Phillips et al.
(2009)
UK
86 73 M=44.8
SD=8.9
Range=27-67
Not Reported Not
Reported
RR=61
PP=17
Not
Recorded=8
CFQ Postal
administration
at one time
point
As a predictor
variable for Quality
of Life (QoL),
measuring self-
reported failures of
attention
8 Royle &
Lincoln
(2008)
160
(Stroke
patients=
70 M=43
SD=11
Range=17-71
Not Reported Not
Reported
Not Reported EMQ Not reported
‘Data were
drawn from two
To analyse the
internal
consistency and
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
UK 90, Healthy
Controls=
98)
sources for
three groups’ (p.
116)
factor structure of
the EMQ
9 Lincoln et al.
(2002)
UK*
223 70 M=43
SD=10
Control
Group age 16
Assessment
Group age 16
Intervention
Group age 16
Not
Reported
Control
Group
SP=35
RR=37
PP=6
Unknown=4
Assessment
Group
SP=33
RR=35
PP=6
Unknown=5
Intervention
Group
SP=26
RR=35
PP=7
Unknown=12
EMQ Face to face
inferred.
Administration
at 2 time points
(4 and 8 months
after
recruitment)
Outcome measure.
To compare EM
between cognitive
assessment,
intervention and
control groups
10 Richardson
(1996)
115 61 M=48.5
Range=32-73
Not Reported Not
Reported
Not Reported EMQ Postal
administration
To classify people
with MS as
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
UK at one time
point.
impaired/
unimpaired for EM,
and to compare
informant and
patients responses
11 Carr et al.
(2014)
UK*
48 69 M=54.3
SD=11.0
Range=34-72
Not Reported Not
Reported
PP=16
SP=8
RR=16
Benign=2
Unknown=2
EMQ Postal
administration
at 3 time points
(baseline, 4 and
8 months after
randomisation)
Primary outcome
measure. To
compare EM
between cognitive
intervention and
control groups
12 Rendell et al.
(2007)
Australia
20
(Healthy
Controls=
20)
80 M=42.9
SD=8.87
Range=29-55
M=13.7
SD=3.77
Not
Reported
RR=18
PP=2
Virtual Week Face to face
board game.
Individual
administration
at one time
point
To compare
prospective
memory between
MS and control
groups.
13 Bruce &
Arnett (2004)
USA
73 79 Non
depressed
M=47.3
SD=9.8
Mild
depressed
Non
depressed
M=14.8
SD=2.4
Mild
depressed
Caucasian Non-
depressed
RR=17
PP=3
SP=7
PR=0
MRS-C Administration
method not
reported.
Administered at
one time point
To investigate
relationship
between
depression and
perceived EM
compared with
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
M=43.1
SD=6.9
Moderate
depressed
M=49.7
SD=6.4
M=14.9
SD=2.6
Moderate
depressed
M=14.9
SD=2.3
Mild-
depressed
RR=14
PP=2
SP=5
PR=0
Moderate
depressed
RR=15
PP=2
SP=6
PR=2
depression and
objective memory
14 Randolph et
al. (2004)
USA
48 77 M=49.6
SD=7.8
M=15.1
SD=2.3
Not
Reported
RR=28
SP=13
PP=6
PR=1
MFQ Face to face
inferred.
Administration
at one time
point
To evaluate the
associations
between mood and
executive function
on metamemory
(MFQ)
15 Erlanger et
al. (2014)
USA
60 72 M=47.9
SD=7.9
Range=26-61
Not High
school
graduate=2%
High School
Degree=27%
Caucasian=
87%
African-
American=5
%
RR=46
SP=14
MFQ
MSNQ
Face to face
inferred.
Administered at
two time points
(45 days apart)
To compare MFQ
and MSNQ (patient
and informant)
with another
cognitive test
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Associate
Degree=18%
Bachelor’s
Degree=28%
Master’s
Degree=21%
Advanced
Degree=5%
Hispanic=5
%
Other=3%
(objective memory)
in order to
evaluate the
validity of the
objective memory
test, and to
compare
correlations
between MS type
16 Thelen et al.
(2014)
USA
86 88 M=47.17
SD=+/-10.56
M=14.9
SD=+/-1.93
Caucasian=
89.4%
African-
American=5
.9%
Hispanic/La
tino=3.5%
Other=1.2%
RR=75
SP=9
PP=2
PRMQ
MIST
Face to face
inferred.
Administered at
one time point
To compare EM
between MS
groups with
polypharmacy and
without
polypharmacy
17 Stuifbergen
et al. (2012)
USA*
61 89 Not Reported High
school=20
Associate
degree=5
Bachelor’s
degree=19
White=89%
African-
American=3
%
Not Reported MSNQ
PDQ
MSNQ:
Administration
method not
reported.
Administered at
3 time points
MSNQ: Outcome
measure. To
compare between
cognitive training
intervention and
control group
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Graduate
degree=17
Multiple
categories=
3%
Other=5%
(baseline, 2 and
5 months
follow-up)
PDQ: Telephone
administration
at one time
point (during
screening)
PDQ: To screen for
eligibility to take
part based on
perceived deficits
18 Bruce et al.
(2010)
USA
79
(Healthy
Controls=
20)
90 M=47.2
SD=10.82
M=14.85
SD=1.96
Caucasian=
87%
African-
American=6
%
Latino=4%
Unspecified
=3%
RR=71
SP=8
PRMQ Face to face
inferred.
Administered at
one time point
To correlate with
other cognitive
tests (objective
memory, executive
function,
information
processing) and
variables (mood
and dissociation)
19 Middleton et
al. (2006)
USA
221
(Healthy
Controls=
31)
74 M=44.8
Range=20-71
M=14.8
Range=10-22
Not
Reported
RR=65%
SP=21%
PP=12%
PR=2%
CFQ Face to face
administration
at home or in
clinic at one
time point
To compare EM
between MS and
control groups, to
correlate with
other cognitive
tests (objective
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
memory), and to
investigate other
variables
(education,
depression,
anxiety, fatigue
and disability) as
predictors of
perceived cognitive
function (CFQ)
20 West et al.
(2007)
USA
1 100 71 Ed.D
(Doctorate in
Education) in
Psychology
Not
Reported
RR=1 PRMQ
Virtual Week
Face to face
administration
at 2 time points
(1 year apart)
Part of a battery of
tests to describe
memory deficit in
one individual case
21 Kardiasmeno
s et al. (2008)
USA
24
(Healthy
Control=
24)
46 M=44.4
SD=8.2
M=15.0
SD=2.0
Not
Reported
RR=8
SP=6
Virtual Week Face to face
administration
at one time
point
To compare PM
between MS and
controls, and as an
outcome measure
to evaluate the
effect of an
implementation-
intentions strategy
on PM
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
22 Demers et al.
(2011)
Canada
30
(Healthy
Control=
24)
67 MS Mild
M=45.9
SD=7.5
MS
Moderate/
Severe
M=44.3
SD=8.5
MS Mild
M=14.1
SD=2.3
MS
Moderate/Se
vere
M=13.2
SD=2.6
Not
Reported
MS Mild
RR=8
SP=3
PP=3
MS
Moderate/Se
vere
RR=7
SP=7
PP=2
PRMQ Face to face
administration
in the lab or at
participants
home.
Administered at
3 time points
(90 minute
sessions)
To correlate EM
with another
variable (mood)
and compare
across MS mild, MS
moderate/severe
cognitive deficit
and control groups
23 Dagenais et
al. (2013)
Canada
41 70 M=44.51
SD=7.43
High
school=12
College=8
University=2
1
Not
Reported
RR=35
SP=6
MSNQ Face to face
inferred.
Administered at
one time point
To correlate
patient and
informant EM with
other variables
(objective memory,
mood and
executive function)
and to evaluate the
concurrent validity
of a cognitive
screening test
24 Cutajar et al.
(2000)
40 70 M=38.67
SD=+/-7.44
Not Reported Not
Reported
RR=40 RBMT Face to face
inferred.
To correlate EM
with other
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Italy Range=20-50 Administered at
4 time points
(one every 9
months)
variables (QoL,
mood and frontal
lobe function)
25 Kujala et al.
(1996)
Finland
45
(Healthy
Control=
35)
Cognitiv
ely
Preserve
d=52.2
Cognitiv
e
Decline=
50
Cognitively
Preserved:
M=43.3
SD=8.7
Cognitive
Decline:
M=43.3
SD=7.2
Cognitively
Preserved:
M=11.6
SD=3.5
Cognitive
Decline:
M=11
SD=2.9
Not
Reported
Cognitively
Preserved:
RR=11
CP=9
SP=3
Cognitive
Decline:
RR=6
CP=13
SP=3
Measure of self-
evaluation of
everyday
memory and
learning
Self-
administered at
one time point
To compare the
pattern of memory
and learning
deficits between
MS cognitively
declined, MS
cognitively
preserved and
control groups, and
to compare with
other cognitive
tests (objective
memory)
26 Campbell et
al. (2016)
UK
62 69 M=49.35
SD=8.88
Range=31-63
Normal
cognitive
performance
M=14.05
SD=2.34
Not
Reported
RR=44
SP=18
MSNQ Face to face
inferred.
Administration
at one time
point
Part of a battery of
questionnaires to
compare QoL,
behaviour and
subjective
impairment
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Cognitively
Impaired
M=13.8
SD=2.78
between MS
normal cognitive
performance and
cognitively
impaired groups
27 Miller et al.
(2014)
USA
96
(Healthy
Control=
29)
78 M=45.5
SD=10.5
M=14.4
SD=2.3
Caucasian=
90%
Africa-
American=3
%
American-
Indian=4%
Hispanic=1
%
Declined=1
%
RR=62
SP=9
PP=2
PR=3
Uncertain=20
MIST Face to face
inferred.
Administration
at one time
point
To compare
prospective
memory between
MS and control
groups and to
correlate with
other variables
(depression and
pain) as a
predicted variable
of PM
impairments.
28 Dagenais et
al. (2016)
Canada
39
(Healthy
Control=
18)
79 M=45 SD=+/-
11.21
Range=20-65
M=14.2
SD=+/- 2.82
Not
Reported
RR=27
SP=5
PP=5
Clinically
isolated
syndrome=2
MSNQ Face to face
inferred.
Administered at
one time point
To screen for
cognitive
dysfunction in MS
alongside other
screening
measures of
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
cognition, anxiety
and depression
29 Moradi et al.
(2016)
Iran
200
(Healthy
Control=
100)
Not
Reporte
d
M=37.96
SD=9.12
Range=22-53
Not Reported Not
Reported
Not Reported PRMQ Administration
method not
reported
To compare
cognitive
performance
between MS and
control groups
alongside
measures of
autobiographical
memory and
working memory
30 Sonder et al.
(2012)
The
Netherlands
121
(informants=
121)
62 Median=53
IQR=45-63
High
education
(College/Univ
ersity)=37
Moderate
education
(Secondary
school)=40
Low
education
Not
Reported
RR=43
SP=40
PP=34
Clinically
isolated
syndrome=4
MSNQ-P MSNQ-
I (Dutch
translation)
Self-
administered
and postal
administered
To investigate
psychometric
properties and
determine the
interpretability
(the degree to
which one can
assign qualitative
meaning to
quantitative
scores) of a Dutch
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
(Primary
school)=42
translation and
correlate it with
measures of
anxiety and
depression,
cognition and
disability
31 Mäntynen et
al. (2014)
Finland*
102 78 Intervention
group
M=43.5
SD=8.7
Control
group
M=44.1
SD=8.8
Intervention
group
M=13.6
SD=2.3
Control
group
M=13.8
SD=2.6
Not
Reported
RR=102
PDQ
MSNQ-P MSNQ-
I
Face to face
inferred.
Administered at
3 time points (
baseline, after 3
months and
after 6 months)
PDQ: one of three
primary outcome
measures to
compare between
MS and control
groups.
MSNQ-P and
MSNQ-I: one of
eleven secondary
outcome measures
to compare
between MS and
control.
32 Rosti-
Otajärvi et al.
(2013)
78 79 Intervention
group
Intervention
group
Not
Reported
RR=78 PDQ
MSNQ-P MSNQ-
I
Face to face
inferred.
PDQ: one of three
primary outcome
measures to
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Finland* M=43.7
SD=8.7
Control
group
M=45.5
SD=9.4
M=13.5
SD=2.4
Control
group
M=13.4
SD=2.6
Administered at
I year follow-up
compare between
MS and control
groups across four
time points.
MSNQ-P and
MSNQ-I: one of
eleven secondary
outcome measures
to compare
between MS and
control groups and
to compare across
four time points.
33 Shevil and
Finlayson
(2010)
USA
35 74.3 M=52.4
SD=10.3
Range=26-70
<12 yrs=3
13-15yrs=13
>15yrs=19
Caucasian=
80%
African-
American=1
4.3%
Other=5.7%
Not Reported MSNQ Telephone
administered at
one time point.
As a phase 1
screening measure
for eligibility
(included if score
was ≥ 23) alongside 
other screening
measures of
fatigue and
depression. It was
supplemented by
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
an objective
screening battery
(phase 2 screening)
34 Benedict et
al. (2008)
USA
76
(Healthy
Control=
25)
74 M=47.6
SD=+/- 8.4
M=14.7
SD=+/- 2.2
Caucasian=
91%
Not
Reported=9
%
RR=63
SP=11
PP=2
MSNQ Administered
face to face at
monthly
intervals for 6
months
following initial
evaluation.
To investigate
reliability as a
screening measure
at monthly
intervals. To
compare between
MS and control
groups, to compare
correlations
between each time
point and as a
predicted variable
across each time
point by measures
of cognition and
depression
35 Carone et al.
(2005)
USA
122
(informants=
122) (Healthy
Control=
72 M=44 SD=8.8 M=14.5
SD=2.1
Caucasian=
92%
RR=88
SP=30
PP=2
RP=2
MSNQ Face to face
inferred.
Administered at
one time point
To compare
discrepancy scores
between MS (and
informants) and
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
37,
informants=3
7)
Not
Reported=8
%
control (and
informants)
groups. To
categorise MS
patients into
groups based on
discrepancy scores.
To correlate with a
battery of
neuropsychological
tests. To
investigate
psychometric
properties
36 Christodoulo
u et al.
(2005)
USA
53 67.9 M=44.2
SD=7.7
Range=20-55
M=14.8
SD=2.2
Range=10-20
Not
Reported
RR=58.5%
SP=37.7%
PP=3.8%
PDQ Administration
method not
reported.
Administered at
2 time points
(baseline and 24
weeks)
One of three
measures of self-
reported cognitive
impairments to
correlate with
neuropsychological
tests
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
37 O’Brien et al.
(2007)
USA
48
(informants=
48) (Healthy
Control=
40,
informants=4
0)
80 M=45.1
SD=9.1
Range=27-56
M=14.7
SD=2.1
Not
Reported
RR=68.8%
PP=10%
SP=21.2%
MSNQ-S
MSNQ-I
Face to face
inferred.
Administered at
one time point
To compare scores
between MS and
healthy control
groups. To
correlate with
other variables
(neuropsychol
ogical functioning,
mood and daily
functioning). As a
predictor variable
of daily functioning
and
neuropsychological
functioning.
To determine its
sensitivity and
specificity
38 Samartzis et
al. (2014)
Greece
100 64 M=40.5
SD=+/- 10.3
Primary
Education=1
9%
Not
Reported
Not Reported PDQ Self-
administered at
one time point
To correlate with
another variable
(depression) and as
a predictor variable
for QoL
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Secondary
Education=5
7%
Tertiary
Education=2
4%
39 Lovera et al.
(2006)
USA
49 76 M=49.3
SD=+/- 7.6
Not Reported Caucasian=
94%
African-
American=1
%
Other
(except
Asian or
Pacific
Islander,
Native
American
or
Hispanic)=2
%
RR=32
SP=15
PP=2
PDQ Postal
administered at
one time point
To correlate with
two measures of
cognitive
impairment and
one measure of
depression
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
40 Pérez-Martín
et al. (2017)
Spain*
62 52 Treatment
Group:
M=44.93
SD=+/-9.89
Control
Group:
M=40.88
SD=+/-8.5
Treatment
Group:
M=10.21
SD=+/- 2.64
Control
Group:
M=11.59
SD=+/- 3.03
Not
Reported
RR=57
SP=2
PP=3
MSNQ Face to face at 2
time points
(baseline and at
3 months post
intervention)
To compare scores
between treatment
and control groups
alongside a battery
of
neuropsychological
tests and other
questionnaires
(anxiety and
depression, fatigue
and QoL) at
baseline and 3
months post
intervention
41 Strober et al.
(2016)
USA
70 81 M=48.97
SD=9.26
M=15.5
SD=2.47
Not
Reported
RR=52
PP=4
SP=13
PR=1
PDQ Administration
method not
reported.
Administered at
one time point.
To correlate
subjective
cognitive concerns
with a battery of
objective
neuropsychological
tests. To correlate
with other
variables of
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
psychological
heath (depression,
anxiety, fatigue
and self-efficacy)
42 Walker et al.
(2016)
Canada
57
(Healthy
Control=
51)
72 M=45.44
SD=9.93
Range=18-59
M=15.44
SD=2.68
Not
Reported
RR=44
SP=9
PP=4
MSNQ-S
MSNQ-I
Face to face
inferred at 2
time points
(baseline and
follow-up
session (one to
three weeks
later))
To compare self
and informant
reported cognition
between MS and
control group at
baseline and follow
up session. To
correlate with a
cognitive
assessment at
baseline and at
follow-up and with
another variable
(depression)
43 Chiaravalloti
et al. (2005)
USA*
28 Experim
ental
Group=6
4
Experimental
Group:
M=45.14
SD=13.78
Experimental
Group:
M=14.64
SD=2.71
Not
Reported
RR=17
PP=4
SP=7
MFQ Face to Face at 3
time points
(baseline, 6
weeks and 11
weeks)
As part of a
neuropsychological
assessment to
compare cognitive
functioning pre and
Paper
#
Author /
Year /
Country
MS group
EM Measure(s)
Use of Measure
Sample Size
Gender
(%F)
Age (years)
Education
(years)
Ethnicity MS Type
How
Administered
Why used
Control
Group=5
7
Control
Group:
M=46
SD=9.28
Control
Group:
M=15.04
SD=2.82
post treatment
between
experimental and
control groups
44 Sullivan et al.
(1990)
Canada
1180
(Healthy
Control=
200)
72 M=49
Range=17-84
M=12.8 Not
Reported
Not Reported PDQ Posted in a
newsletter at
one time point.
To evaluate
psychometric
properties
Note. Key: *RCTs: randomised control trials, a: statistics include MS, TBI and stroke patients.
Abbreviations: CAMPROMPT: Cambridge Prospective Memory Test; CFQ: Cognitive Failures Questionnaire; EM: Everyday memory; EMQ: Everyday
Memory Questionnaire; IQR: interquartile range; M: Mean; MFQ: Memory Functioning Questionnaire; MIST: Memory for Intentions Screening Test; MRS:
Memory Rating Scale; MS: Multiple Sclerosis; MSNQ: MS Neuropsychological Questionnaire (MSNQ-P: patient self-report version; MSNQ-I: Informant
version); PDQ: Perceived Deficits Questionnaire; PP: primary progressive; PR: progressive-relapsing; PRMQ: Prospective and Retrospective Memory
Questionnaire; QoL: Quality of life; RBMT: Rivermead Behavioural Memory Test; RR: Relapsing-remitting; SD: Standard deviation; SP: secondary
progressive.
